This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Exscientia Management

Management criteria checks 1/4

Exscientia's CEO is Dave Hallett, appointed in Feb 2023, has a tenure of 1.75 years. directly owns 0.001% of the company’s shares, worth €6.95K. The average tenure of the management team and the board of directors is 1.8 years and 3.9 years respectively.

Key information

Dave Hallett

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.8yrs
CEO ownership	0.001%
Management average tenure	1.8yrs
Board average tenure	3.9yrs

Recent management updates

Recent updates

CEO

Dave Hallett (55 yo)

1.8yrs

Tenure

Dr. David Hallett, also known as Dave, Ph.D. is the Chief Operations Officer of Exscientia Limited since January 2020. He served as Chief Operating Officer at Exscientia plc since June 2022 until 2022 and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Hallett	Chief Scientific Officer	1.8yrs	no data	0.0011% € 7.0k
Ben Taylor	CFO, Chief Strategy Officer & Executive Director	4yrs	UK£1.92m	0.061% € 369.6k
John Overington	Chief Technology Officer	less than a year	no data	0.015% € 90.5k
Sara Sherman	Vice President of Investor Relations	no data	no data	no data
Dan Ireland	Executive VP of Legal & Company Secretary	1.8yrs	no data	no data
Parker Moss	Executive Vice President of Corporate Development	less than a year	no data	no data
Caroline Rowland	Chief People Officer	2.2yrs	no data	no data
Richard Law	Chief Business Officer	no data	no data	no data
Nikolaus Krall	Executive Vice President of Precision Medicine	1.8yrs	no data	no data
Marie-Louise Fjallskog	Interim Chief Medical Officer & Clinical Development Lead	less than a year	no data	no data

1.8yrs

Average Tenure

55yo

Average Age

Experienced Management: 0RK's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
David Hallett	Chief Scientific Officer	less than a year	no data	0.0011% € 7.0k
Ben Taylor	CFO, Chief Strategy Officer & Executive Director	4yrs	UK£1.92m	0.061% € 369.6k
Elizabeth Crain	Independent Non-Executive Chairman	3.8yrs	UK£282.03k	0.088% € 531.8k
Mario Polywka	Independent Non-Executive Director	7.2yrs	UK£201.69k	0.052% € 315.1k
Robert Ghenchev	Independent Non-Executive Director	4.5yrs	no data	no data
Franziska Michor	Independent Director	1.5yrs	UK£178.86k	0.028% € 167.6k

3.9yrs

Average Tenure

51yo

Average Age

Experienced Board: 0RK's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/11/22 10:00
End of Day Share Price	2024/11/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exscientia plc is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Alec Stranahan	BofA Global Research
Chris Shibutani	Goldman Sachs
Brendan Smith	TD Cowen

This company listing is no longer active

Exscientia Management

Management criteria checks 1/4

Key information

Recent management updates

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Exscientia plc, Annual General Meeting, May 15, 2024

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Less than half of directors are independent

Recent updates

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Third quarter 2024 earnings released: UK£0.40 loss per share (vs UK£0.25 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.36 loss per share (vs US$0.37 loss in 2Q 2023)

Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million.

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for

New major risk - Revenue and earnings growth

The Schall Law Firm Announces Class Action Lawsuit Against Exscientia plc

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.38 loss in 1Q 2023)

Exscientia plc to Report Q1, 2024 Results on May 21, 2024

Holzer & Holzer, LLC Files Class Action Lawsuit on Behalf of Exscientia P.L.C. Investors

Exscientia plc, Annual General Meeting, May 15, 2024

New minor risk - Shareholder dilution

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc to Report Fiscal Year 2023 Results on Mar 21, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: UK£0.25 loss per share (vs UK£0.29 loss in 3Q 2022)

Exscientia plc to Report Q3, 2023 Results on Nov 09, 2023

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc to Present New Preclinical Data for AI- Designed LSD1 and MALT1 Inhibitors at ESMO 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 2Q 2022)

Exscientia plc to Report Q2, 2023 Results on Aug 10, 2023

Exscientia plc Initiates Prospective Observational Study in Ovarian Cancer

Exscientia plc Announces First Patient Enrolled in Phase 1/2 ELUCIDATE Trial Assessing GTAEXS617 in Advanced Solid Tumours

First quarter 2023 earnings released: US$0.38 loss per share (vs US$0.17 loss in 1Q 2022)

Exscientia plc Highlights "The Future of AI-Enabled Drug Discovery" at SLAS Europe

Exscientia plc to Report Q1, 2023 Results on May 24, 2023

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Full year 2022 earnings released: UK£0.97 loss per share (vs UK£0.99 loss in FY 2021)

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

Exscientia plc Highlights New Data to Identify Patients That Are More Likely to Respond to Its A2a Receptor Antagonist, Exs-21546

Exscientia plc Receives First clinical trial application Approval to Initiate IGNITE-AI, Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours

Third quarter 2022 earnings released: UK£0.29 loss per share (vs UK£59.17 loss in 3Q 2021)

Exscientia plc to Report Q3, 2022 Results on Nov 15, 2022

Blood Cancer Discovery Publication Further Validates Exscientia's Ai Precision Medicine Platform for Improving Patient Outcomes

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Second quarter 2022 earnings released: UK£0.23 loss per share (vs UK£0.71 loss in 2Q 2021)

Exscientia plc to Report Q2, 2022 Results on Aug 17, 2022

Exscientia plc Reports Data from EXS-21546 Phase 1A Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers

Exscientia plc to Report Q1, 2022 Results on May 25, 2022

Less than half of directors are independent

Exscientia plc, Annual General Meeting, May 18, 2022

Exscientia plc Appoints Michael Krams as Chief Quantitative Medicine Officer

High number of new directors

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources